The immune cells were at a 7 times higher ratio in lung samples from men than women, and may explain sex differences between ...

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more ...

Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development ------ John Adams, PhD Appointed Chief Scientific ...

The PAH treatment market is expected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, at a CAGR of ...

San Antonio Spurs superstar Victor Wembanyama will likely miss the rest of the season because of deep vein thrombosis. What ...

Pulmonary hypertension, despite advances in treatment, still has a poor prognosis, which is often associated with right heart failure, and for which pulmonary arterial hypertension (PAH) is a severe ...

Researchers from Morphic Therapeutic Inc. and affiliated organizations published data from a study that aimed to assess the potential of using arginylglycylaspartic acid (RGD) integrins for the ...

Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge ...

Lungpacer Medical today announced positive results from a Phase 1 clinical study evaluating its neurostimulation technology ...

Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary ...